Phathom Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada to vonoprazan, a potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan, which is in Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. Phathom Pharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Earnings for Phathom Pharmaceuticals, Inc. (PHAT)
Earnings in 2023 (TTM): $-201,592,000
According to Phathom Pharmaceuticals, Inc.'s latest financial reports the company's current earnings (TTM) are $-201,592,000. The earnings displayed on this page is the company's Pretax Income.
Earnings history of Phathom Pharmaceuticals, Inc.
Annual Earnings
| Year | Income Before Tax | Net Income |
|---|---|---|
| 2023 | $-201,592,000 | $-201,592,000 |
| 2022 | $-197,723,000 | $-223,006,000 |
| 2021 | $-143,883,000 | $-148,094,000 |
| 2020 | $-129,068,000 | $-133,318,000 |
| 2019 | $-255,131,000 | $-209,744,000 |
| 2018 | $-1,288,000 | $-1,288,000 |